Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

导出 OA

翻译打印收藏纠错

作者： Francesco,Marchesi ^[1] ; Irene,Terrenato ^[2] ; Elena,Papa ^[3] ; Martina,Tomassi ^[3] ; Paolo,Falcucci ^[3] ; Svitlana,Gumenyuk ^[3] ; Francesca,Palombi ^[3] ; Francesco,Pisani ^[3] ; Daniela,Renzi ^[3] ; Atelda,Romano ^[3] ; Antonio,Spadea ^[3] ; Giulia,Regazzo ^[4] ; Maria Giulia,Rizzo ^[4] ; Mafalda,De Rienzo ^[5] ; Claudio,Ripellino ^[6] ; Simona,Sgromo ^[3] ; Caterina,Viggiani ^[3] ; Eleonora,Ponte ^[7] ; Ramy,Kayal ^[8] ; Iole,Cordone ^[9] ; Maria Laura,Foddai ^[5] ; Andrea,Mengarelli ^[3]

作者单位： Hematology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 55, 00144, Rome, Italy. francesco.marchesi@ifo.it. ^[1] Department of Research, Advanced Diagnostics and Technological Innovation, Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[2] Hematology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 55, 00144, Rome, Italy. ^[3] Department of Research, Advanced Diagnostics and Technological Innovation, Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[4] Immuno-Transfusional Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[5] Health Economics & Real-World Evidence Freelance, Milan, Italy. ^[6] Leukapheresis and Cellular Therapy Unit, S. Camillo-Forlanini Hospital, Rome, Italy. ^[7] Radiology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[8] Clinical Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. ^[9]

关键词 Autologous stem cell transplant Biosimilars Granulocyte colony-stimulating factors Lymphoma Myeloma Peg-filgrastim